Late Health Outcomes After Contemporary Lymphome Malin de Burkitt Therapy for Mature B-Cell Non-Hodgkin Lymphoma: A Report From the Childhood Cancer Survivor Study -

Late Health Outcomes After Contemporary Lymphome Malin de Burkitt Therapy for Mature B-Cell Non-Hodgkin Lymphoma: A Report From the Childhood Cancer Survivor Study
Information type: Other primary research
Source: Journal of Clinical Oncology
Specialities: Cancers | Haematological disorders | Neurological disorders | Paediatric and neonatal medicine
Summary
Analysis of health outcomes for those treated with the Lymphome Malin de Burkitt (LMB) chemotherapy regimen (n = 126), survivors of NHL treated with non-LMB regimens (n = 444), and siblings (n = 1,029) suggests increased neurotoxicity associated with LMB regimen.
UKMi comment
Increased risk for the following specific neurologic conditions were observed in LMB survivors compared with non-LMB survivors: epilepsy, balance problems, tremors, weakness in legs, severe headaches, and prolonged arm, leg, or back pain.
Related links: